Data from orthogonal approaches (siRNA and shRNA knockdown) and various models (EGFRmut and KRASG12C lung cancer; in vitro and in vivo) consistently show that knockdown of PRMT1 reduces persistence when combined with oncogene-targeting drugs but does not reduce general cell fitness when used alone. This evidence concerns the gene PRMT1 and lung carcinoma.